Vaccination against human papillomavirus in Switzerland: simulation of the impact on infection rates
- PMID: 19795095
- DOI: 10.1007/s00038-009-0081-3
Vaccination against human papillomavirus in Switzerland: simulation of the impact on infection rates
Abstract
Objectives: Human papillomavirus (HPV) is a sexually transmitted infection of particular interest because of its high prevalence rate and strong causal association with cervical cancer. Two prophylactic vaccines have been developed and different countries have made or will soon make recommendations for the vaccination of girls. Even if there is a consensus to recommend a vaccination before the beginning of sexual activity, there are, however, large discrepancies between countries concerning the perceived usefulness of a catch-up procedure and of boosters. The main objective of this article is to simulate the impact on different vaccination policies upon the mid- and long-term HPV 16/18 age-specific infection rates.
Methods: We developed an epidemiological model based on the susceptible-infective-recovered approach using Swiss data. The mid- and long-term impact of different vaccination scenarios was then compared.
Results: The generalization of a catch-up procedure is always beneficial, whatever its extent. Moreover, pending on the length of the protection offered by the vaccine, boosters will also be very useful.
Conclusions: To be really effective, a vaccination campaign against HPV infection should at least include a catch-up to early reach a drop in HPV 16/18 prevalence, and maybe boosters. Otherwise, the protection insured for women in their 20s could be lower than expected, resulting in higher risks to later develop cervical cancer.
Similar articles
-
Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada.Hum Vaccin Immunother. 2018 Jan 2;14(1):118-123. doi: 10.1080/21645515.2017.1385688. Epub 2017 Dec 13. Hum Vaccin Immunother. 2018. PMID: 29049007 Free PMC article.
-
[Impact of vaccination against oncogenic human papillomavirus on the incidence and mortality of cervical cancer in Germany].Med Klin (Munich). 2007 Jul 15;102(7):515-23. doi: 10.1007/s00063-007-1065-9. Med Klin (Munich). 2007. PMID: 17634869 German.
-
Facilitators and barriers of human papillomavirus vaccine uptake in young females 18-26 years old in Singapore: A qualitative study.Vaccine. 2019 Sep 24;37(41):6030-6038. doi: 10.1016/j.vaccine.2019.08.053. Epub 2019 Aug 28. Vaccine. 2019. PMID: 31473002
-
Human papillomavirus vaccines: current status and future prospects.Drugs. 2010 Jun 18;70(9):1079-98. doi: 10.2165/10898580-000000000-00000. Drugs. 2010. PMID: 20518577 Review.
-
[Cervical HPV infection; epidemiology and vaccination].Kansenshogaku Zasshi. 2008 Nov;82(6):609-12. doi: 10.11150/kansenshogakuzasshi1970.82.609. Kansenshogaku Zasshi. 2008. PMID: 19086414 Review. Japanese. No abstract available.
Cited by
-
Successful implementation and results of an HPV vaccination program in Geneva Canton, Switzerland.Public Health Rep. 2015 May-Jun;130(3):202-6. doi: 10.1177/003335491513000306. Public Health Rep. 2015. PMID: 25931623 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources